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Saposins A, B, C and D are derived from a common precursor, prosaposin (psap). The few patients with sapo-
sin C deﬁciency develop a Gaucher disease-like central nervous system (CNS) phenotype attributed to dimin-
ished glucosylceramide (GC) cleavage activity by acid b-glucosidase (GCase). The in vivo effects of saposin
C were examined by creating mice with selective absence of saposin C (C2/2) using a knock-in point
mutation (cysteine-to-proline) in exon 11 of the psap gene. In C2/2 mice, prosaposin and saposins A, B
and D proteins were present at near wild-type levels, but the saposin C protein was absent. By 1 year, the
C2/2 mice exhibited weakness of the hind limbs and progressive ataxia. Decreased neuromotor activity
and impaired hippocampal long-term potentiation were evident. Foamy storage cells were observed in
dorsal root ganglion and there was progressive loss of cerebellar Purkinje cells and atrophy of cerebellar
granule cells. Ultrastructural analyses revealed inclusions in axonal processes in the spinal cord, sciatic
nerve and brain, but no excess of multivesicular bodies. Activated microglial cells and astrocytes were pre-
sent in thalamus, brain stem, cerebellum and spinal cord, indicating regional pro-inﬂammatory responses.
No storage cells were found in visceral organs of these mice. The absence of saposin C led to moderate
increases in GC and lactosylceramide (LacCer) and their deacylated analogues. These results support the
view that saposin C has multiple roles in glycosphingolipid (GSL) catabolism as well as a prominent function




late endosome (1). Each saposin is an 80 amino acid lysosomal
glycoprotein with a role in enhancing the activity of speciﬁc
cognate enzymes in GSL degradation (2). Saposin B presents a
speciﬁcGSL,sulfatide,toitshydrolase,arylsulfataseA,forclea-
vagetogalactosylceramide(3).Inbothhumansandmice,saposin
B deﬁciency results in sulfatide accumulation and a metachro-
matic leukodystrophy-like disease that is similar to arylsulfatase
A deﬁciency (4,5). Saposin C interacts with GCase, leading to
optimal activity (6). Biochemical studies have shown that in
addition to its activation function toward GCase, saposin C
protects GCase from proteolytic degradation (7). Point
mutations in saposin C lead to a Gaucher-like disease due to
diminished GC cleaving activity in cells (8,9). Both saposin
B and C have in vitro effects on hydrolysis of LacCer
by activation of galactosylceramide-b-galactosidase, GM1-
b-galactosidase and other b-galactosidases (10). In vitro,
saposins A and C enhance GCase activity in the presence of
negatively charged phospholipids, but saposin A and C have
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Advance Access published on December 16, 2009different membrane interaction modes (11,12). In vivo, saposin
A and C speciﬁcally enhance the activities of
galactosylcerebrosidase and GCase, respectively (13).
Saposin D facilitates acid ceramidase degradation of ceramide
to sphingosine and fatty acids (14).
The structure of saposin C is restrained by three disulﬁde
bonds (15). Biophysical studies have shown that saposin C has
membrane fusion properties (16,17). This fusion occurs by the
formation of intervesicular saposin C dimers as a bridge
between acidic phospholipid vesicles (18). This fusogenic prop-
erty is thought tobe involved inthe maturation ofmultivesicular
bodies (19). Dissection of the saposin C peptide and in vitro and
in vivo studies indicate regional localization of these multiple
functions to speciﬁc regions of the protein, including neurito-
genic activity and GCase activation (20). The fusogenic and
neuritogenic activities localize to the 40 amino acids of the N-
terminal, whereas the COOH-half contains the GCase activation
domain (20). The former functions can be duplicated with the
appropriate saposin C peptide fragments. In comparison, acti-
vation of GCase requires the COOH-half within a ‘saposin’
structure with intact disulﬁde bonds. The N-terminal 35–40
aminoacidsequenceisnotcriticaltothisGCaseactivationfunc-
tion, as the corresponding peptide sequence from saposin B can
fulﬁll the overall requirements (20,21).
Point mutations of human saposin C present as variants of
Gaucher disease. A neuronopathic (type 3) variant phenotype
was associated with a C385F mutation, whereas an apparent
non-neuronopathic variant occurred in the presence of an
L394P substitution (8,9,22). The neuronopathic variant
showed a progressive neurological deterioration and increased
GC levels in the brain (9).
To facilitate dissection of the physiological roles of saposin
C, a mouse containing a knock-in of a cysteine-to-proline sub-
stitution in saposin C was created. The resultant saposin C-
deﬁcient mice presented with slowly developing neurological
impairment that correlated with mild GSL accumulation and
CNS pathology.
RESULTS
Generation and veriﬁcation of saposin C-deﬁcient mice
The codon for the ﬁfth cysteine of saposin C was mutated
(Cys!Pro) in the targeting vector (Fig. 1A) to destroy the dis-
ulﬁde bond that stabilizes the saposin C protein (4). The recom-
binant ES cells were screened by PCR and conﬁrmed by
Southern blot analysis (Fig. 1B). The mutation in saposin C
was conﬁrmed by DNA sequencing. To remove the neo gene
in the targeting vector, heterozygous F1 mice were bred with
ZP3-Cre transgenic mice. Subsequently, the Cre transgene
was eliminated by crosses into WT C57BL6 mice (Fig. 1C).
No differences in phenotype or histology were observed
between saposin C2/2 mice with or without the neo gene.
Bothsexes were usedinthe analyses,and nodifferences inphe-
notypeorbiochemistrywerefound.Mendelianratiosofsaposin
C2/2 mice were obtained from the heterozygote crosses. Het-
erozygote (saposin Cþ/2) mice were normal phenotypically
and biochemically and indistinguishable from WT. The
saposin C2/2 male and female mice attained the weight of
WT litter mates and were fertile at maturity.
The protein levels of prosaposin and the individual saposins
in saposin C2/2 mice were determined by immunoblot
analyses. Saposin C protein was not detected in ﬁbroblasts
(Fig. 2A) or tissues (data not shown) from saposin C2/2
mice using our anti-mouse saposin C antibody. The level of
prosaposin in saposin C2/2 mouse ﬁbroblasts was slightly
higher than that in WT mice detected with our anti-mouse
saposin D antibody (Fig. 2B). Saposin A, B and D protein in
saposin C2/2 liver and cultured ﬁbroblasts were 50–
70% of WT levels.
Phenotype and neurobehavioral assessments
Saposin C2/2 mice slowly developed neurological impair-
ment and lived up to 24 months. The onset of neurological def-
icits began at 10–12 months with progressive wobbling, lack
of coordination, hind limb weakness and abnormal leg reﬂexes
(Fig. 3). Ataxia developed after 12 months. No differences in
phenotype were observed between males and females.
Neurobehavioral studies were conducted at 9 and 13 months
in male saposin C2/2 mice. On the narrow bridges test,
saposin C2/2 mice exhibited signiﬁcant increases in latency
and foot slips on round (11, 17 and 28 mm) (Fig. 4A) and
square (12 and 25 mm) (data not shown) beams relative to
WT mice. All saposin C2/2 mice failed to cross the 5 mm
square beam, whereas WT mice had no difﬁculty traversing
the bridge (data not shown). Saposin C2/2 mice showed
increases in latency and number of slips with age. The elevated
zero-maze tests for anxiety and fearfulness. Saposin C2/2
mice spent longer times in open areas than WT control mice
and concurrently had fewer open area entries (Fig. 4B),
suggesting a decrease in anxiety-like behavior. Spontaneous
locomotion testing measures exploratory and motor functions.
Compared with age-matched WT mice, saposin C2/2 mice
showed greater vertical activity (rears) within the 60 min of
testing, further suggesting a reduction of exploratory anxiety
(Fig. 4C). Horizontal activity (total distance) was not signiﬁ-
cantly different in saposin C2/2 mice from WT mice
(Fig. 4C). These results indicate that deﬁciency of saposin C
affects movement, coordination, anxiety behaviors.
Long-term potentiation (LTP) was measured in the hippo-
campus at 4 and 24 months Compared with WT mice,
saposin C2/2 mice showed signiﬁcantly reduced LTP at 24
months (Fig. 5), suggesting deﬁciency of saposin C altered
hippocampal plasticity, a cellular marker associated with
learning and memory. No signiﬁcant difference in LTP was
observed in the mice at 4 months (data not shown).
Histopathological analyses
Saposin C2/2 mice had foamy storage material in the dorsal
root ganglion starting at 25 weeks. Larger axonal spheroids
were evident in the dorsal horn of the spinal cord (Fig. 6A). No
storage cells were visible in the brain. Pro-inﬂammation in
saposin C2/2 mice was assessed using anti-CD68 and anti-
GFAPantibodystaining(Fig.6B).CD68isanintracellularmem-
brane glycoprotein that is expressed in quiescent and activated
tissue macrophages (23). GFAP is an astrocytic marker. The
enhanced GFAP signals indicate astrogliosis. Clearly enhanced
CD68 and GFAP signals were found in spinal cord, brainstem,
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mice compared with WT mice. Disease progression was
evident in H&E stained parafﬁn sections of spinal cord and cer-
ebellum in 3–19-month-old saposin C2/2 mice (Fig. 6C).
Axonal spheroids were present in spinal cord dorsal horn after
6 months, but absent at 3 months. The Purkinje cell layer in cer-
ebellar lobule IV was normal at 3 months. Loss of Purkinje cells
was observed after 6 months.TUNEL assays of parafﬁn sections
werenegativesuggestingthatlossofPurkinjecellswasnotbyan
apoptotic mechanism. Visceral organs in saposin C2/2 mice
were not distinguishable from WT mice.
Loss of Purkinje cells in the cerebellum was evident at 2
months and progressed chronologically from lobule III to X,
demonstrated by anti-calbindin antibody staining (Fig. 7A),
such that by 24 months Purkinje cells were absent in lobules
III to VIII. Calbindin staining revealed the degeneration of
Purkinje cell axons in molecular layers and the appearance
of spheroids in neuronal processes in cerebellar white matter
of saposin C2/2 mice (Fig. 7B). In addition, granule cell
atrophy was demonstrated by decreased NeuN-stained cells
in the granule cell layer (Fig. 7D). The Purkinje cell loss
was subsequent to granule cell atrophy. Cerebellar reduction
in C2/2 was particularly evident at .20 months (Fig. 7A
and C). In the same regions, increases in astrogliosis and
activated microglial cells were evident (Fig. 7D).
Ultrastructural analyses revealed that axonal and neuronal
processes contained electron-dense complex membrane whirl
inclusions in saposin C2/2 mice at 18 months (Fig. 8).
The storage inclusion materials are heterogeneous and mem-
brane bound bodies. The inclusion bodies were found in
spinal cord, brainstem, midbrain, cortex, hippocampus, cer-
ebellum and sciatic nerve. The sciatic nerve exhibited
inclusion bodies and degenerating myelin layers. More neur-
onal processes containing inclusions were observed at 18 or
22 months than that at 10 months. No inclusions or excesses
of multivesicular bodies were found in cerebral neurons or
Purkinje cells at 10, 18 and 22 months (Fig. 8).
Biochemical analysis
GSLs in 13-month-old saposin C2/2 mice showed increases
in spinal cord GC (1.4-fold) and GS (1.3-fold) compared with
WT mice (Fig. 9A and B). The LacCer levels (Fig. 9C) in the
spinal cord were unchanged, but LacSph (Fig. 9D) was
2.3-fold higher than in the WT controls. In the cerebellum,
the GC and GS of saposin C2/2 mice were at WT levels
at 13 months. Both LacCer and LacSph accumulated in the
saposin C2/2 mouse cerebellum to 1.9- and 1.6- fold of
WT levels, respectively. No signiﬁcant changes of ceramides
and hydroxy ceramides were found in the cerebellum or
spinal cord. The cerebral cortex, midbrain, liver and lung of
saposin C2/2 mice had no signiﬁcant alteration of GSLs
relative to the WT control.
Figure 1. Targeting construct and veriﬁcation. (A) Schematic map of the saposin C targeting construct. Individual saposins are encoded by the exons underlined
with a dotted line. The mutation in the saposin C (Cys!Pro) domain was in prosaposin exon 11. The point mutation destroyed one of three disulﬁde bridges
within saposin C, which leads to a deﬁciency in saposin C protein. The neo gene was removed by recombination of two loxP sites by cross-breeding of saposin C
heterozygotes and Zp3-Cre transgenic mice. B, BamHI; Bgl, BglII; H, HindIII; E, EcoRI; Ev, EcoRV; X, XbaI; Xho, XhoI; Nhe, NheI; Sal, SalI;  mutation site.
(B) Correct targeting of ES cells was conﬁrmed by Southern blot. The clones were digested by HindIII for 50 probe and EcoRI for 30 probe. (C) PCR genotyping
of saposin C mice before and after Cre recombination using primers C–F and C–R across the loxP site.
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strate (24). In comparison to WT mice, saposin C 2/2 mice
at 2 months showed decreases in GCase activity by 50%
in liver, lung, spleen and brain (Fig. 10A). GCase protein
levels in saposin C2/2 liver were 67% of WT levels
(Fig. 10B). GCase activity and protein level in heterozygote
(saposin Cþ/2) mice were not different from that in WT
mice.
DISCUSSION
To understand the functions of saposin C in vivo, a saposin C-
deﬁcient mouse was created in the presence of near-normal
amounts of saposins A, B and D that are derived from prosa-
posin. The primary manifestations in the saposin C2/2
mouse were of neurodegeneration that was slow in onset and
slow to progress. Within the CNS, the spinal cord and cerebel-
lum were the primary organs involved and in particular
showed axonal ballooning, neuronal loss and axonal deterio-
ration, particularly in the spinal cord. In the cerebellum,
granule cell loss was followed by Purkinje cell loss that
progressed from lobules III to X, with resultant decreases in
cerebellar size. Within the cerebellum, astrogliosis and some
inﬁltration by CD68þ microglial cells indicated a signiﬁcant
pro-inﬂammatory reaction. Importantly, at both the light
microscopic and the ultrastructural levels, the cerebral cortical
neurons and hippocampal neurons were unchanged compared
with saposin Cþ/2 littermates, yet hippocampal LTP in
Schaefer collaterals was severely reduced. Biochemically,
minor storage of GC and GS was present in the spinal cord,
and some increases in LacCer and LacSph were present in
the cerebellum, with minor changes in LacSph in the spinal
cord. No histological storage was evident in visceral tissues,
and the levels of GSL in the visceral tissues were normal.
The deﬁciency of saposin C as well as the resultant histologi-
cal and biochemical changes in the CNS and in the viscera,
were accompanied by decreases in GCase activity and
protein, thus verifying the effect of saposin C as a proteolytic
protector for GCase within the lysosome (7). These ﬁndings
provide insight into the functions of saposin C independent
of its function in the degradation of GC, and highlight poten-
tial previously unrecognized functions related to LacSph.
Because of the ultrastructural inclusions evident in axons of
the saposin C2/2 mice, the current ﬁndings indicate cellular
effects on axonal transport and secondary retrograde neuronal
degeneration. Interestingly, the previously observed increase
in multivesicular body formation in prosaposin-deﬁcient
mouse models (25) was not seen in the isolated saposin C-
deﬁcient mice described here.
The data presented demonstrate that saposin C is a non-
essential enhancer for GC degradation in vivo at the levels pro-
duced in these mice in vivo, i.e. GCase residual activity is
present, whereas with an essential activator, a total deﬁciency
of GCase function would exist. The total absence of GCase is
incompatible with extra uterine survival in the mouse.
However, saposin C optimizes the hydrolysis of GC by
GCase (12), and probably also of GS. Importantly, saposin
C is a stabilizer of GCase in lysosomes, protecting it from pro-
teolytic digestion (7). When saposin C is absent in the pres-
ence of a detrimental mutation in GCase, the activity of
GCase drops below a threshold level and enhances the
accumulation of GC and GS in various tissues (Sun et al., in
review). Thus, saposin C appears to be an optimizer of
GCase activity: it interacts with GCase, whether mutant or
WT, and protects these enzymes against proteolytic digestion
by lysosomal proteases.
Although total deﬁciency did not lead to massive increases
in GC or GS in all tissues, excluding the spinal cord, saposin C
could facilitate the hydrolysis of other GSLs in vivo. Speciﬁ-
cally, in vitro saposin C is involved in the metabolism of
LacCer and ceramide (26). Also, both saposin C and B
enhance the degradation of LacCer (10). The unchanged
levels of LacCer in the saposin C deﬁcient mice in the visceral
tissues, cerebral cortex and spinal cord, were not unexpected
since saposin B can compensate for the deﬁciency of
saposin C. In addition, the normal levels of ceramide in the
saposin C deﬁcient mice indicate a compensatory effect of
saposins D and C in the degradation of ceramide by acid cer-
amidase (27,28).
Of interest were the signiﬁcant increases in LacCer and
LacSph in the cerebellum of the saposin C deﬁcient mice.
Such accumulations, particularly of LacCer, were also found
in prosaposin deﬁciency and in Niemann-Pick C mice
(29–31). LacCer is a bioactive lipid that has been shown to
participate in osteoclastogenesis, angiogenesis and neural
inﬂammation (32–34). The biological activities of LacSph
havenotbeenwellstudied,butinanalogytootherlysophinogli-
pids, GS and galactosylsphingosine, this lysolipid probably has
signiﬁcant toxicity to sensitive tissues, including neurons.
Indeed,LacSphmobilizescalciuminisolatedbrainmicrosomes
Figure 2. Saposin protein expression. (A) Saposin C was not detected in the
ﬁbroblasts using anti-mouse saposin C antibody. Saposin A and B were
detected by anti-mouse saposin A and B antibodies, respectively. (B) Prosapo-
sin and saposin D were detected with anti-mouse saposin D antibody. Prosa-
posin levels in saposin C2/2 ﬁbroblasts were slightly increased compared
to the WT control. b-Actin was used as a loading control.
Figure 3. Phenotype of saposin C2/2 mice at 16 months. (Left) Saposin
C2/2 mouse showing hind paw spreading suggesting paralysis. (Right)
Saposin C2/2 mouse with abnormal hindleg positioning and WT mouse
with a normal V shape position in tail-hanging reﬂex.
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to neuropathological consequences and neuronal inﬂam-
mation. Similar to several other lysosomal storage diseases
(36,37), saposin C deﬁcient mice showed sensitivity of Pur-
kinje cells to the disease state. Why this should be true for Pur-
kinje cells, and secondarily granule cells that show speciﬁc
degeneration in particular lysosomal storage diseases and in
the saposin C deﬁcient mice, is unknown, but this sensitivity
has now been observed in several models, including saposin
D, Niemann-Pick C, Niemann-Pick A, Chediak-Higashi syn-
drome, neuronal ceroid lipofucinoses and lysosomal acid
phosphatase (36–41), indicating vulnerability of these cells
to metabolic abnormalities including GSL.
In prosaposin-deﬁcient mice and humans, ﬁbroblasts and
other tissues have been shown to have increased numbers of
multivesicular bodies (42,43). This has led to the suggestion
that prosaposin and its function in GSL metabolism may be
critical to the formation of multivesicular bodies, endosomes
and lysosomes (42,44). However, in the CNS of the saposin
C deﬁcient mice no increase in multivesicular bodies
was observed by EM studies. These studies were applied to
both cortical neurons and the Purkinje cells. Consequently,
Figure 4. Neurobehavioral assessment. (A) Narrow bridges test. WT and saposin C2/2 mice were tested on 11, 17 and 28 mm round beams at 9 and 13 months.
Saposin C2/2 mice showed signiﬁcant increases of latency (left) across the beam and foot slips (right) compared with WT. Latency and number of slips in
saposin C2/2 mice progressively increased with age. (B) Zero-maze test. Relative to WT, saposin C2/2 mice had fewer entries and spent longer time in the
open area. (C) Locomotor activity. (Left) Saposin C2/2 mice exhibited signiﬁcantly enhanced vertical activity (P , 0.02) compared with WT. (Right) Total
distance activity in saposin C2/2 mice was not different from WT (P , 0.1). Activity was recorded every 5 min over a 60-min period. WT and saposin C2/2
male mice were used in the tests.  P   0.05;   P   0.01;    P   0.001. WT, n ¼ 16; saposin C2/2, n ¼ 21.
638 Human Molecular Genetics, 2010, Vol. 19, No. 4multivesicular bodies formation does not appear to be a mech-
anism involved in pathologic degeneration in the cortex, cer-
ebellum or spinal cord. Cell death caused by apoptosis was
unlikely in these mice as suggested by negative TUNEL
assay. However, saposin C may have additional functions in
cellular metabolism beyond that for the degradation of
GSLs, particularly GC, GS, LacCer and LacSph. As is
evident in the spinal cord, retrograde axonal degeneration
was present as evidenced by the large deposits in the dorsal
horn of the spinal cord. This correlated with the presence of
inclusion bodies within the axons and suggests a mechanism
of retrograde degeneration caused by saposin C deﬁciency.
The precise role in this transport process and potential
release at synapses remains to be elucidated, but it seems to
be fundamental to the pathological processes within the CNS.
The clinical and pathological phenotype presented in
saposin C2/2 mice was primarily related to neuronal dys-
function. Massive Purkinje cell death occurred in cerebellum.
The spheroids that contained inclusion bodies were found in
axons. These pathological defects correlated with the pheno-
type of ataxia and decreased coordination in saposin C2/2
mice. Axonal spheroids have been noted in several lysosomal
storage diseases, including Niemann-Pick C, GM2 gangliosi-
doses, a-N-acetylgalactosaminidase and a-mannosidosis
(45–48). Early ﬁndings on these lysosomal disease animal
models suggest that the loss of Purkinje cells is secondary to
axonal dystrophy (48). The axonal dystrophy may affect ante-
rograde or retrograde transport, which can cause axonal
degeneration and cell death, as suggested in Alzheimer’s
disease and other neurodegenerative disorders (49,50).
Deterioration of neuromotor function and impaired hippocam-
pal LTP could be the result of such axonal dysfunction.
Saposin C is a lysosomal protein, and lysosomes in the
neuron are located in the soma. Further studies will be




Reagents from commercial sources: anti-fade/DAPI, methyl
green, ABC Vectastain and alkaline phosphatase kit II
(Black) (Vector Laboratory, Burlingame, CA), DIG Easy
Hyb, anti-digoxigenin-AP, CDP-Star, positively charged
nylon membranes and Lumi-ﬁlm chemiluminescent detection
ﬁlm (Roche Applied Science, Indianapolis, IN), Qiagen Quick-
change II XL kit (Qiagen, Inc., Valencia, CA), restriction
enzymes (New England Labs, Beverly, MA), NuPAGE
4–12% Bis–Tris gel, NuPAGE MES SDS running buffer,
AlexaFluor488 goat anti-mouse IgG (HþL) (Invitrogen, Carls-
bad, CA), 4-methylumbelliferyl-b-D-glucopyranoside (4MUG,
Sigma), M-PER Mammalian Protein Extraction Reagent and
BCA protein assay reagent (Pierce, Rockford, IL) and
HybondTM–ECLTM nitrocellulose membrane and ECL detec-
tion reagent (Amersham Biosciences, Piscataway, NJ).
Construction of targeting vector and generation of saposin
C2/2mice
Saposin C-deﬁcient mice were created by knocking in a codon
change to create the substitution cysteine-to-proline (C!P)
substitution in saposin C. This mutation eliminates one of
this protein’s three disulﬁde bridges and results in a selective
deﬁciency in this saposin. The same strategy has been used
previously (4,28,38,51). The mouse prosaposin genomic
DNA clones and targeting vector (OSdupdel) were kindly pro-
vided by Dr Kunihiko Suzuki. The knock-in saposin C was
created using a Qiagen Quick-change II XL kit with mis-
matched oligonucleotide primers: C5F (50-AGC TCT CTG
CCC GGG GTG ATC GGC CTC TG-30), C5R (50-CA GAG
GCC GAT CAC CCC GGG CAG AGA GCT-30). The mis-
matched nucleotides are underlined. The short arm of the
1.2 kb Nhe I–Xho I fragment was generated by PCR using a
pBluescript subclone 7–9 containing exons 8–15 of the
mouse prosaposin gene as a template. The resultant product
was cloned into the TopoTA (PCR II) vector. Using the
same subclone 7-9, the long arm of 4.2 kb Sal I–Xba I frag-
ments encoding Cys!Pro was generated by PCR and
cloned into the Sal I/Xba I sites of the TA cloning vector.
The OSdupdel vector contains polymer enhancer/herpes
simplex virus thymidine kinase (MC1) promoter with the neo-
mycin (neo) gene ﬂanked by two loxP sites and the thymidine
kinase (TK) gene driven by the 30 phosphoglycerate kinase
(PGK) promoter (30). The long arm (4.2 kb) carrying the
requisite mutation was ligated into SalI/XbaI sites downstream
of MC1-neo and formed the 30 homologous region. The short
arm (1.2 kb) was cloned into NheI/XhoI sites upstream of
MC1-neo in the vector and formed the 50 homologous
region. The sequences of long arm and short arm were con-
ﬁrmed by direct sequencing. The targeting vector was linear-
ized by Not1 and introduced into a 129/SvEv ES cell line.
Figure 5. Electrophysiology analysis of long-term potentiation (LTP). The
fEPSPs were recorded from parasagittal sections (350 mm) of hippocampal
CA1 region using the MED64 multielectrode array system to determine the
slope of resulting EPSPs. The slopes of the EPSPs (LTP) in 24-month-old
saposin C2/2 mice (closed circle) were signiﬁcantly (P , 0.05) decreased
compared with WT mice (open circle) for 90 min following stimulation.
WT, n ¼ 7 mice; saposin C2/2, n ¼ 6 mice.
Human Molecular Genetics, 2010, Vol. 19, No. 4 639Figure 6. CNS pathology in C2/2 mice. (A) The parafﬁn sections of dorsal root ganglion and dorsal horn of spinal cord from 15-month-old saposin Cþ/2 or
C2/2 mice were stained with H&E. Foamy storage material (arrows) was present in the dorsal root ganglion neurons of saposin C2/2 mice. Larger axonal
spheroids (arrows) were present in the spinal cord dorsal horn of these mice. As a control, saposin Cþ/2 mice had normal morphology in dorsal root ganglion
and spinal cord. (B) CNS proinﬂammation in saposin C2/2 mice demonstrated by anti-GFAP (B1-B3) and anti-CD68 (B4-B6). (B1) WT spinal cord, (B2)
saposin C2/2 spinal cord and (B3)C 2/2 midbrain at 15 months showed astrogliosis with enhanced GFAP (green) signal. The nucleus was labeled by
DAPI (blue). (B4) C2/2 dorsal horn of spinal cord. (B5) C2/2 thalamus. (B6) C2/2 brain stem. Microglial cells were stained by anti-CD68 antibody
(brown) in 24-month-old saposin C2/2 mice. Tissue sections were counterstained with hematoxylin. (C) H&E stained parafﬁn sections of spinal cord and
cerebellum from saposin C2/2 mice at 3, 6, 12 and 18 months. Axonal spheroids were present in dorsal horn of spinal cord at 6, 12 and 18 months, but
absent at 3 months. Purkinje cell layer (arrows) in cerebella lobule IV was normal at 3 months. Loss of Purkinje cells ( ) was evident at 6 months and older.
640 Human Molecular Genetics, 2010, Vol. 19, No. 4Figure 7. Pathology in cerebellum. (A) Anti-calbindin antibody stained Purkinje cells (brown) in 24-month-old Cþ/2 and C2/2 mouse brain. Loss of Purkinje
cells in saposin C2/2 mice progressed from cerebella lobule III to X with age. Increases of astrogliosis demonstrated by anti-GFAP antibody staining (brown)
were in the region where the Purkinje cells were lost. Normal Purkinje cell layers and astrocytes were found in the Cþ/2 cerebellum. (B) Calbindin staining
revealed axon and neuronal processes in the molecular layer and white matter of the cerebellum. (B1) Normal Purkinje cells and axons (arrows) in Cþ/2 mouse.
(B2) Degeneration of Purkinje cell axons (stars) in the molecular layer of cerebella lobule X in 24-month-old C2/2 mouse. (B3) Neuronal processes in Cþ/2
cerebella white matter. (B4) Neural spheroids (arrows) presented in the neuronal processes of C2/2 mouse. (C) 24-month-old Cþ/2 and C2/2 mouse cer-
ebellum. The white bars show the height of cerebellum. The size of saposin C2/2 cerebellum was reduced at 24 months. (D) Atrophy in the granule cell layer of
saposin C2/2 mice. NeuN staining cells (green) were decreased in the granulecell layer of cerebella lobule III from 24-month-old C2/2 mice compared with
lobule III of Cþ/2 mouse. The white bar in the photo shows the diameter of the granule cell layer. Both GFAP (brown) and CD68 (brown) signals were
enhanced in lobule III of the saposin C2/2 mouse. Sections stained with calbindin and GFAP were counterstained with methyl green (green). CD68-stained
sections were counterstained with hemotoxilin.
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clones using the primers ﬂanking outside of the short arm:
C-ES F1-25 (50-GGTAGCATTGCATGTCTTAGCGCTG-30)
and inside of the short arm: C-ES F5 (50-GAGTGGGTCTG
TTCTGAACATTGCTT-30), in combination with the primer
in the 50 region of neo, NEO2R (50-AAC CAC ACT GCT
CGA CAT TGG GTG-30). The recombinant clones generated
1.6 kb and the wild-type (WT) clones had 1.4 kb PCR products,
respectively. The recombinant ES clones were further con-
ﬁrmed by Southern blot analysis. Identiﬁed recombinant ES
cells were ampliﬁed and DNA (10 mg) from each clone was
digested with HindIII or EcoRI. Southern blots were probed
with DIG labeled 50 or 30 probes (28). In the recombinant ES
clones, HindIII digestion generated 8.3 kb WT and 9.5 kb
recombinantfragments,identiﬁedby50-probeandEcoRIdiges-
tion, and resulted in 9.2 kb WT and 8.3 kb recombinant frag-
ments with the 30-probe. The mutations in the recombinant
cloneswereveriﬁedbyPCRandsequencing.Correctlytargeted
clones were used to generate chimeric mice by microinjection
into C57BL/6J blastocysts. Electroporation, ES cell culture,
selection and chimera breeding were carried out by the Gene-
Targeting Mouse Service Core at the University of Cincinnati.
To remove the neo gene, the heterozygous F1 mice were
crossed into Zp3-Cre mice (C57BL/6-TgN(Zp3-Cre)93Knw
purchased from The Jackson Laboratory) (52) as described
(28). The strain of background for saposin C2/2 is C57BL/
6J/129SvEV. All mice were maintained in micro-isolators,
with the exception of those going through behavior, in accord-
ance with institutional guidelines under IACUC approval at
Cincinnati Children’s Research Foundation.
PCR genotyping
PCR reaction was conducted for routine mouse colony geno-
typing using the genomic DNA from clipped tails. After vali-
dation by sequencing of the mutations within saposin C, the
loxP site was used as a marker for the point mutation genotyp-
ing with the primers C loxP F (50-CAGATACCCCATCC
TCCCATGG-30) and C loxP R (50-TGTGAAGGACAAG
AGGAGAGTG-30). The PCR product of WT was 200 bp,
mutant with neo was 1.4 kb and without neo was 307 bp.
Histological studies
Following CO2 narcosis, mice were perfused with saline and
then 4% paraformaldehyde. The tissues were dissected and
ﬁxed in 10% formalin, embedded in parafﬁn, sectioned and
stained with hemotoxilin and eosin (H&E). Parafﬁn sections
of cerebellum were stained with mouse anti-calbindin D28K
(Sigma, C9848) and mouse anti-GFAP (Sigma, G3893). The
antibodies were diluted 1/500 or 1/200 in PBS with 3% goat
serum and 0.2% Triton X-100, respectively. Detection was
with ABC Vectastain and the alkaline phosphatase kit II
(Black), according to the manufacturer’s instructions. The
slideswerecounterstainedwithmethylgreen.Forimmunoﬂuor-
escence staining, frozen sections from 4% paraformaldhyde
ﬁxed tissues were incubated with mouse anti-GFAP (1/200).
Parafﬁn sections were reacted with mouse anti-NeuN (1/100)
(Chemicon, MAB377). The antibodies were diluted in PBS
with 3% normal goat serum and 0.2% Triton X-100. Both bioti-
nylated goat anti-mouse and streptavidin-conjugated ﬂuor-




Figure 8. Ultrastructural studies. (A) The spinal cord of saposin Cþ/2 mice
at 18 months had normal morphology. (B) The spinal cord of saposin C2/2
mice at 18 months showed inclusion bodies (arrows) in neuronal process. (C)
Enlarged view of inclusion bodies in (B). (D) Cortical neuron in saposin
C2/2 mice at 10 months had normal morphology. (E) Axonal inclusions
(arrow) in granule cell layer of saposin C2/2 cerebellum at 18 months. (F)
Purkinje cells in saposin C2/2 mouse at 10 months had normal morphology.
(G) The sciatic nerve of saposin C2/2 mice at 18 months had inclusion
materials (arrows) and degenerating myelin layers (arrowheads). (H) Axonal
inclusion material (arrow) in the midbrain of saposin C2/2 mice at 18
months.
642 Human Molecular Genetics, 2010, Vol. 19, No. 4on the frozen sections was as described (53). Karnovsky’s
ﬁxative was used for ultrastructural studies.
Immunoblot
Tissues or cell extracts (50–200 mg) were prepared in M-PER
(Mammalian Protein Extraction Reagent) and separated on
NuPAGE 4–12% Bis–Tris gel with NuPAGE MES SDS
running buffer, and electro-blotted on HybondTM–ECLTM
nitrocellulose membranes. The membranes were blocked in
3% BSA for 1 h, followed by incubation overnight with the
rabbit anti-mouse saposin D, C, A or B antibodies (1/500 in
0.15% milk and 1% BSA) to detect individual saposins and
prosaposin (28). Mouse anti b-actin monoclonal antibody
(1/10 000 in 2% w/v dry milk) was applied to detect b-actin.
The signal was developed using ECL detection reagent
Figure 9. GSL analyses. Spinal cord and cerebellum lysate were analyzed for GC, GS, LacCer and LacSph. Saposin C2/2 mice had signiﬁcant increases of GC,
GS and LacSph in the spinal cord. LacCer and LacSph increased in the C2/2 cerebellum. The amounts of lipids were normalized to phosphate in each sample.
Age-matched 13-month-old WT and C2/2 mice were used in the assay (n ¼ 3).  P   0.05 and   P   0.01.
Human Molecular Genetics, 2010, Vol. 19, No. 4 643according to the manufacturer’s instructions. Protein concen-
tration was determined using BCA protein assay reagent.
GCase activity and protein
Mouse GCase activity assay (54) and protein detection was
described previously (55). The amounts of GCase proteins
were quantitated by ImageQuant software relative to the
amount of b-actin in the same sample.
Tissue GSL analyses
Monohexosylceramides (GC and galactosylceramide), LacCer,
GS,lactosylsphingosine(LacSph)andceramidewerequantiﬁed
by LC/MS in the Lipidomic Core at the Medical University of
South Carolina (56). Because C2/2 mice had normal levels
of saposin A and galactosylceramidase, C2/2 and WT mice
should have the same levels of galactosylceramide. Conse-
quently,thealterationsofmonohexosylceramideintheanalyses
reﬂect changes in GC. The GSL contents were normalized to
phosphate content in the same sample after lipid extraction
from tissue lysate. Three animals from each genotype were
included in the analyses. Data were analyzed by Student’s
t-test using GraphPad Prism 5.0 software.
Behavioral studies
The behavioral tests were conducted in the Animal Behavioral
CollaborativeCoreatCincinnatiChildren’sResearchFoundation.
Narrow bridges. Square beams (1 m) 25, 12 and 5 mm wide
and round beams (1 m) with diameters of 28, 17 and 11 mm
were used as described (57). The mice were trained by traver-
sing the 12 mm beam for three consecutive days, four trials per
day. Animals were considered to be trained when they crossed
the 12 mm beam in ,20 s. The test phase began on the fourth
day. Each mouse in turn received two consecutive trials (up to
60 s/trial) on each square or round beam in a progression from
widest to narrowest. Latency to traverse each beam and the
number of times the hind foot slipped off the beam were
recorded. A total of 26 saposin C2/2 mice at 13 months
and 17 WT male mice were tested as sex (male) and age-
matched groups. Data were analyzed by Student’s t-test
using GraphPad Prism 5.0 software.
Figure 10. GCaseactivityandproteininC2/2 mice.(A)GCaseactivitylevelsweredecreasedinC2/2 liver,lung,brainandspleenby 50%relativetotheWT
level. (B) The GCase protein level in the C2/2 liver was 67% of the WT level. Age-matched 2-month-old WT and C2/2 mice were used in the assay (n ¼ 3).
644 Human Molecular Genetics, 2010, Vol. 19, No. 4Tail-hanging reﬂex observations. Mice were lifted by the tail
to observe the leg reﬂexes every month. The legs of normal
mice assume a V position, whereas the affected mice with
advanced disease exhibited an abnormal position of the legs
and clasped paws. The age at ﬁrst development of this
abnormality was recorded.
Elevated zero-maze test. The apparatus was ring-shaped, and
behavior was recorded with an overhead camera connected
to a DVD-R. The circular runway was 105 cm in diameter
with a 10 cm path width. Two quadrants of the ring were
enclosed by black acrylic sidewalls and two quadrants were
open; the latter had a 1 cm clear acrylic curb to prevent slip-
ping off the edge. Overhead lights were turned off; a single
dim halogen light source was used. Mice were placed in the
enclosed quadrant and tested for 5 min. Test sessions were
recorded and scored later for time in open area, head dip fre-
quency and number of open area entries. A total of 26 saposin
C2/2 male mice at 13 months and 17 age-matched WT male
mice were tested. Data were analyzed by Student’s t-test using
GraphPad Prism 5.0 software.
Locomotor activity. Locomotor activity was measured in a
41   41   30 cm Accuscan activity monitor equipped with
16 pairs of photodetector-LED beams along the x and y axes
(Accuscan Electronics with VersaMax software, Columbus,
OH). The test was conducted under normal overhead ﬂuor-
escent light. Individual mice were placed in the chambers
for 60 min. The apparatus was cleaned with 70% ethanol
between animals. Total horizontal distance and vertical
activity (rears) were recorded in 5-min intervals. Saposin
C2/2 (n ¼ 26) and WT (n ¼ 17) male mice were tested at
13 months. Data were analyzed with a mixed model 2-way
analysis of variance (Proc GLM, SAS, SAS Institute, Cary,
NC) with interval as the repeated measure.
Electrophysiology
Electrophysiology was performed using the MED64 multi-
electrode array system (Alpha Med Sciences) as described
(4). Parasagittal sections (350 mm) were taken from the hippo-
campus of male WT (n ¼ 7) and C2/2 mice (n ¼ 6) at 24
months. Stimulation and recording of resulting fEPSPs were
from the Schaffer collateral pathway of the CA1 region of
the hippocampus. Slopes of EPSPs following high-frequency
stimulation were recorded for 90 min. Brain slices were
recorded in duplicate for each animal and the data were
averaged per animal. Data were recorded using Performer
2.0 software (Alpha Med Sciences). Data were analyzed
using repeated measures ANOVA with gene as a between
subject factor and time as a within subject factor, the repeated
measure were the fEPSP measurements following LTP
induction.
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